Novo Nordisk Shares Climb as Wegovy Sales Reassure Investors.

Novo Nordisk A/S saw a rise in shares due to strong sales of the weight-loss treatment Wegovy, surpassing analyst estimates. Despite recent investor concerns, the company remains confident in its next-generation obesity treatment, CagriSema. Novo is competing with Eli Lilly in the obesity drug market, which is expected to reach $130 billion by the end of the decade. The company anticipates continued growth and is working to increase production capacity to meet demand. [Extracted from the article]